Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in PH-IIP
NCT02138825Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (PH-IIP) comparing Riociguat with Placebo (2 arms). Primary endpoint: Mean Change in 6 Minute Walking Distance at 26 weeks. Started Jun 2014; status: terminated.
02
Drugs
riociguat
03
Conditions
Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (PH-IIP)
Beyond the preview
Go deeper on NCT02138825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138825.